Plectin recombinant protein: a key cytoskeletal linker protein regulating prostate cancer growth and metastasis

Author: Senior Product Manager of UA Views：13

This article focuses on the molecular characteristics and biological functions of Plectin, systematically elaborating its high expression features as a cytoskeletal linker protein in localized and metastatic prostate cancer tissues, analyzing the inhibitory effects of Plectin knockout on prostate cancer cell growth in vitro, clonogenic formation, and in vivo xenograft tumor growth, and exploring the impact of Plectin loss on distant metastatic colonization and overall metastatic burden as well as its proteomic mechanisms.

Recent Advances
Product Information

Recent Advances

Plectin Recombinant Protein: A Key Cytoskeletal Linker Protein in the Regulation of Prostate Cancer Growth and Metastasis

Summary: This article focuses on the molecular characteristics and biological functions of Plectin, systematically elaborating its high expression features as a cytoskeletal linker protein in localized and metastatic prostate cancer tissues, analyzing the inhibitory effects of Plectin knockout on prostate cancer cell growth in vitro, clonogenicity, and xenograft tumor growth in vivo, and discussing the impact of Plectin loss on distant metastatic colonization and overall metastatic burden as well as its proteomic mechanisms.

I. The Therapeutic Dilemma of Prostate Cancer and the Research Background of Plectin.

Prostate cancer causes more than 30,000 deaths annually in the United States, primarily attributable to incurable metastatic disease. Compared with benign prostate tissue, high levels of Plectin are associated with localized and metastatic human prostate cancer. This expression difference suggests that Plectin may play an important functional role in the development and progression of prostate cancer, and also provides a basis for considering it as a potential therapeutic target. Once prostate cancer progresses to metastatic disease, the efficacy of existing treatment approaches becomes extremely limited. Therefore, elucidating the key molecules that drive prostate cancer growth and metastasis has urgent clinical significance for developing new intervention strategies.

II. High Expression and Functional Validation of Plectin in Prostate Cancer.

Recently, researchers have elucidated that compared with benign prostate tissue, high levels of Plectin are associated with localized and metastatic human prostate cancer. Knockout of Plectin can inhibit prostate cancer cell growth in vitro and clonogenicity, as well as prostate cancer xenograft growth in vivo. Plectin knockout can further interfere with invasive and invasive cellular behaviors assessed by in vitro migration, invasion, and wound healing. These results indicate that Plectin is not only required for prostate cancer cell proliferation but is also a key molecular basis for maintaining their invasive phenotype. As a cytoskeletal linker protein, Plectin maintains the integrity of the cytoskeletal network by cross-linking intermediate filaments, actin microfilaments, and microtubules. The proliferation inhibition and decreased invasive capacity caused by its loss reflect the central role of cytoskeletal integrity in the malignant behavior of tumor cells.

III. Impact of Plectin on Distant Metastatic Colonization of Prostate Cancer.

Consistently, distant site metastatic colonization of Plectin gene knockout cells was impaired, including liver, lung, kidney, bone, and the genitourinary system. Plectin gene knockout inhibited the number of metastases in each organ and reduced the overall metastatic burden. This comprehensive inhibition of multi-organ metastatic colonization indicates that Plectin plays an important role in multiple steps of prostate cancer metastasis——from initial invasion and intravasation, to survival in the circulation, and then to colonization and growth in distant organs. Bone is the most common site of distant metastasis in prostate cancer, and the inhibitory effect of Plectin knockout on bone metastasis suggests that it may be involved in the interaction between prostate cancer cells and the bone microenvironment.

IV. Proteomic Mechanisms of Plectin in Regulating Prostate Cancer Growth and Metastasis.

To gain deeper insight into the role of Plectin in prostate cancer growth and metastasis, researchers performed proteomic analysis on prostate cancer Plectin knockout xenograft tissues. Gene set enrichment analysis indicated that protein levels related to extracellular matrix and laminin interactions were increased, while protein levels regulating amino acid metabolism, cytoskeletal proteins, and cellular stress responses were decreased. This proteomic signature reveals the metabolic and structural remodeling that occurs in tumor cells after Plectin loss——the upregulation of extracellular matrix and laminin-related proteins may reflect the enhanced compensatory dependence of tumor cells on the extracellular environment after losing Plectin, while the downregulation of amino acid metabolism, cytoskeletal proteins, and stress response proteins is consistent with the decreased proliferative capacity and stress adaptation of tumor cells. Plectin knockout can inhibit prostate cancer cell growth, and this phenotype corroborates the aforementioned proteomic changes, jointly supporting the conclusion that Plectin is an important regulator of prostate cancer cell growth and metastasis.

V. Conclusion.

In Plectin-related basic research and drug development, high-quality recombinant Plectin protein is a core tool for dissecting the binding mechanisms between Plectin and cytoskeletal components and interacting proteins. In response to the needs of Plectin functional research and prostate cancer mechanism exploration, UIA provides Plectin His Tag Protein, Human. This product is suitable for applications such as binding activity analysis of Plectin with cytoskeletal components including intermediate filaments, actin, and microtubules, screening and validation of Plectin-interacting proteins, functional research of Plectin in prostate cancer growth and metastasis, and development of therapeutic strategies targeting Plectin.

As a cytoskeletal linker protein, Plectin has become an important regulator of prostate cancer growth and metastasis by virtue of its high expression features in localized and metastatic prostate cancer tissues, its key supporting role in prostate cancer cell growth in vitro and xenograft tumor growth in vivo, and its comprehensive regulatory capacity for distant metastatic colonization in multiple organs including liver, lung, kidney, bone, and the genitourinary system. From the inhibition of cell proliferation and invasive behavior by Plectin knockout, to the reduction of multi-organ metastatic burden, and further to the remodeling of extracellular matrix and metabolic pathways revealed by proteomics, Plectin continues to drive the in-depth development of research on prostate cancer metastasis mechanisms. Plectin His Tag Protein, Human provides reliable tool support for mechanistic research on the Plectin signaling network and the development of targeted therapeutic strategies, and will continue to facilitate innovative exploration in the field of precision treatment for prostate cancer.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next